Neuroendocrine tumours trials in Japan
6 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 2RecruitingTrial-stage medicine
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Chuo-ku, Kyoto, Nankoku, Sapporo, Tokyo, Yokohama
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075EU 2023-504853-11-00Registry updated 2026-11-03
Phase 3RecruitingTrial-stage medicine
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Aichi, Nagoya, Chiba, Kashiwa, Ehime, Matsuyama, Fukuoka, Fukuoka, Hokkaido, Sapporo, Ishikawa, Kanazawa, Kanagawa, Yokohama, Kyoto, Kyoto, Miyagi, Sendai, Okayama, Okayama, Osaka, Osaka, Shizuoka, Sunto-gun, Tokyo, Chuo-ku
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654EU 2025-523869-22-00Registry updated 2026-10-28
Phase 1/2Not yet recruitingTrial-stage medicine
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Hokkaido, Sapporo, Kanagawa, Kawasaki, Osaka, Hirakata, Shizuoka, Sunto-gun
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895EU 2026-525634-27-00Registry updated 2026-10-27
Phase 1RecruitingTrial-stage medicine
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Chuo Ku
- Age
- 18 years to 100 years
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727EU 2024-519111-34-00Registry updated 2026-09-22
Phase 2RecruitingTrial-stage medicine
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Aichi, Nagoya, Chiba, Kashiwa, Miyagi, Sendai, Osaka, Osaka, Osaka, Sakai, Tokyo, Chuo-ku, Tokyo, Koto-ku
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058EU 2023-504247-13-00Registry updated 2026-07-23
Phase 1/2RecruitingTrial-stage medicine
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Where
- Chuo Ku, City
- Age
- 18 years and over
- People
- 27 worldwide
- Run by
- Tanabe Pharma America, Inc.
See details and how to joinNCT06943521Registry updated 2025-12-11
All Neuroendocrine tumours trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.